Bracco Imaging Celebrates ANVISA Approval of AiMIFY™ in Brazil for Enhanced MRI Diagnostics
Bracco Imaging S.p.A., a prominent name in diagnostic imaging, recently celebrated a significant milestone with the ANVISA (Agência Nacional de Vigilância Sanitária) approval of its AiMIFY™ software in Brazil. This approval represents a notable expansion for Bracco in Latin America, following earlier clearances by the U.S. Food and Drug Administration (FDA) and CE Marking in Europe, further establishing the company’s position as a global leader in innovative imaging solutions.
What is AiMIFY™?
AiMIFY™ is a cutting-edge AI-powered software designed to enhance Magnetic Resonance Imaging (MRI) scans of the brain, utilizing Gadolinium-Based Contrast Agents (GBCAs). The technology is engineered to optimize contrast enhancement, effectively amplifying the visibility of lesions that may be small or exhibit poor enhanced characteristics. This advancement ensures that radiologists receive improved contrast information, allowing for more accurate diagnoses. The software's robust performance has been validated across a diverse patient demographic, varying pathologies, multitude of lesion sizes, different MRI sequences, and scanner vendors, all contributing to its broad applicability in clinical practice.
A Commitment to Innovation
Sascha Daeuber, the Global Radiology Platform Leader at Bracco Imaging, expressed pride in the company’s ongoing effort to introduce AiMIFY™ to Brazil, stating, “This milestone reflects our continued commitment to advancing precision diagnostics.” He emphasized that AiMIFY™ aids radiologists in gaining clearer insights from brain MRIs, which is crucial for improved patient outcomes.
Impact on Latin American Healthcare
Tommaso Montemurno, General Manager for Latin America at Bracco Imaging, noted that MRI stands as the primary imaging modality in the region. Bracco has cultivated a comprehensive portfolio of innovative products, ranging from advanced contrast agents to high-performing injectors and IT solutions. This strong foundation sets the stage for AiMIFY™ to significantly elevate diagnostic standards and enhance the capabilities of radiologists throughout Latin America by offering innovative tools.
Strategic Partnership with Subtle Medical
The collaboration with Subtle Medical, known for its AI imaging solutions, underscores a shared dedication to improving global access to advanced medical imaging technologies. Josh Gurewitz, Chief Commercial Officer at Subtle Medical, touted the importance of AiMIFY™, stating, “This is a key step in our mission to improve global access to advanced medical imaging.” The combination of AiMIFY™ and SubtleHD™ enables imaging providers to unlock enhanced diagnostic precision while optimizing operational efficiencies without necessitating expensive hardware upgrades.
Future Prospects
Both Bracco Imaging and Subtle Medical are committed to continuing their partnership in providing innovative imaging solutions that not only enhance diagnostic accuracy but also improve patient care. The introduction of AiMIFY™ into Brazil exemplifies a forward-thinking approach to healthcare, aiming to meet the growing demand for advanced imaging resources in one of Latin America's most vital healthcare markets.
The approval of AiMIFY™ by ANVISA marks not just a milestone for Bracco Imaging but also a major step forward in the realm of diagnostic imaging. As the healthcare landscape continually evolves, the implementation of such technologies is pivotal in ensuring that diagnostic services meet the ever-increasing standards of accuracy and efficiency. For additional information about Bracco's offerings or to access full product prescribing details, interested parties are encouraged to visit Bracco.
What is AiMIFY™?
AiMIFY™ is a cutting-edge AI-powered software designed to enhance Magnetic Resonance Imaging (MRI) scans of the brain, utilizing Gadolinium-Based Contrast Agents (GBCAs). The technology is engineered to optimize contrast enhancement, effectively amplifying the visibility of lesions that may be small or exhibit poor enhanced characteristics. This advancement ensures that radiologists receive improved contrast information, allowing for more accurate diagnoses. The software's robust performance has been validated across a diverse patient demographic, varying pathologies, multitude of lesion sizes, different MRI sequences, and scanner vendors, all contributing to its broad applicability in clinical practice.
A Commitment to Innovation
Sascha Daeuber, the Global Radiology Platform Leader at Bracco Imaging, expressed pride in the company’s ongoing effort to introduce AiMIFY™ to Brazil, stating, “This milestone reflects our continued commitment to advancing precision diagnostics.” He emphasized that AiMIFY™ aids radiologists in gaining clearer insights from brain MRIs, which is crucial for improved patient outcomes.
Impact on Latin American Healthcare
Tommaso Montemurno, General Manager for Latin America at Bracco Imaging, noted that MRI stands as the primary imaging modality in the region. Bracco has cultivated a comprehensive portfolio of innovative products, ranging from advanced contrast agents to high-performing injectors and IT solutions. This strong foundation sets the stage for AiMIFY™ to significantly elevate diagnostic standards and enhance the capabilities of radiologists throughout Latin America by offering innovative tools.
Strategic Partnership with Subtle Medical
The collaboration with Subtle Medical, known for its AI imaging solutions, underscores a shared dedication to improving global access to advanced medical imaging technologies. Josh Gurewitz, Chief Commercial Officer at Subtle Medical, touted the importance of AiMIFY™, stating, “This is a key step in our mission to improve global access to advanced medical imaging.” The combination of AiMIFY™ and SubtleHD™ enables imaging providers to unlock enhanced diagnostic precision while optimizing operational efficiencies without necessitating expensive hardware upgrades.
Future Prospects
Both Bracco Imaging and Subtle Medical are committed to continuing their partnership in providing innovative imaging solutions that not only enhance diagnostic accuracy but also improve patient care. The introduction of AiMIFY™ into Brazil exemplifies a forward-thinking approach to healthcare, aiming to meet the growing demand for advanced imaging resources in one of Latin America's most vital healthcare markets.
The approval of AiMIFY™ by ANVISA marks not just a milestone for Bracco Imaging but also a major step forward in the realm of diagnostic imaging. As the healthcare landscape continually evolves, the implementation of such technologies is pivotal in ensuring that diagnostic services meet the ever-increasing standards of accuracy and efficiency. For additional information about Bracco's offerings or to access full product prescribing details, interested parties are encouraged to visit Bracco.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.